← Leaderboards
Sanjay Rajagopalan
Case Western Reserve University
$28,940,369
Attributed
$38,173,148
Total exposure
21
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,173,148 · 21
By mechanism
R01$23,671,257 · 10
R35$4,994,501 · 1
P50$4,096,067 · 1
U01$3,797,172 · 1
R21$1,114,480 · 3
T32$499,671 · 1
Top collaborators
- Shyam Biswal8 shared
- David L Wilson8 shared
- Robert D Brook5 shared
- Andrei Maiseyeu5 shared
- Matthew R. Weir5 shared
- Myung H Park2 shared
- Jayakumar Sahadevan2 shared
- Taehoon Shin2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- David L Wilson$18,775,702
- Shuo Li$964,771
- Sadeer Al-Kindi$371,198
- Prerna Singh$54,538
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsLinkAir PollutionMediatingPhenotypeInflammationCardiovascular SystemMetabolicBaseResponseMorbidity - Disease RateParticulate MatterNon-Insulin-Dependent Diabetes MellitusExposure ToCardiovascular Risk FactorInflammatoryMortalityInsightInsulin ResistanceRisk FactorsDiabetes MellitusPlayAnimalsPredisposition
Grant awards (91)
ACHIEVE P3 - CHD$1,007,970
P50 · FY2025 · MD · contact PI
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$920,087
R35 · FY2025 · ES · contact PI
Cardiovascular risk from comprehensive evaluation of the CT calcium score exam$767,135
R01 · FY2025 · HL
Pericoronary fat: MACE risk from non-contrast CT and the role of iodine perfusion in contrast CT$766,570
R01 · FY2025 · HL
Targets and targeting of immunometabolism in chronic PM2.5 exposure$402,500
R01 · FY2025 · ES
Targets and targeting of immunometabolism in chronic PM2.5 exposure$94,385
R01 · FY2025 · ES
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$952,577
R35 · FY2024 · ES · contact PI
Cardiovascular risk from comprehensive evaluation of the CT calcium score exam$770,193
R01 · FY2024 · HL
Pericoronary fat: MACE risk from non-contrast CT and the role of iodine perfusion in contrast CT$762,378
R01 · FY2024 · HL
ACHIEVE P3 - CHD$710,664
P50 · FY2024 · MD · contact PI
Targets and targeting of immunometabolism in chronic PM2.5 exposure$402,500
R01 · FY2024 · ES
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$57,747
R35 · FY2024 · ES · contact PI
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$960,396
R35 · FY2023 · ES · contact PI
ACHIEVE P3 - CHD$920,418
P50 · FY2023 · MD · contact PI
Cardiovascular risk from comprehensive evaluation of the CT calcium score exam$799,168
R01 · FY2023 · HL
Pericoronary fat: MACE risk from non-contrast CT and the role of iodine perfusion in contrast CT$786,146
R01 · FY2023 · HL
Cardiovascular risk from comprehensive evaluation of the CT calcium score exam$767,638
R01 · FY2023 · HL
Targets and targeting of immunometabolism in chronic PM2.5 exposure$402,500
R01 · FY2023 · ES
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$120,325
R35 · FY2023 · ES · contact PI
Diversity Suppplement (CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$62,577
R35 · FY2023 · ES · contact PI
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$960,396
R35 · FY2022 · ES · contact PI
ACHIEVE P3 - CHD$585,120
P50 · FY2022 · MD · contact PI
Targets and targeting of immunometabolism in chronic PM2.5 exposure$402,500
R01 · FY2022 · ES
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution$960,396
R35 · FY2021 · ES · contact PI
ACHIEVE P3 - CHD$871,895
P50 · FY2021 · MD · contact PI
MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSOCLEROSIS (MAGMA)$508,052
R01 · FY2020 · HL · contact PI
Investigating Effect of Air pollution and Host Defenses in SARS-CoV2 infection$450,313
U01 · FY2020 · ES
NON-CONTRAST-ENHANCED PERIPHERAL MR ANGIOGRAPHY$369,070
R01 · FY2020 · HL · contact PI
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure$251,065
R01 · FY2020 · ES · contact PI
COUNTERACT Supplement--ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure$124,998
R01 · FY2020 · ES · contact PI
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$635,267
U01 · FY2019 · ES
MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSOCLEROSIS (MAGMA)$616,422
R01 · FY2019 · HL · contact PI
NON-CONTRAST-ENHANCED PERIPHERAL MR ANGIOGRAPHY$367,243
R01 · FY2019 · HL
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure$298,463
R01 · FY2019 · ES · contact PI
Transcultural lessons in the Management of Heart Failure TRANSMEDHF$120,000
R21 · FY2019 · HL
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$716,210
U01 · FY2018 · ES
MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSOCLEROSIS (MAGMA)$601,587
R01 · FY2018 · HL · contact PI
Air Pollution and Hypertension: Vascular Mechanisms$494,558
R01 · FY2018 · ES · contact PI
NON-CONTRAST-ENHANCED PERIPHERAL MR ANGIOGRAPHY$382,243
R01 · FY2018 · HL
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure$341,081
R01 · FY2018 · ES · contact PI
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$244,936
U01 · FY2018 · ES
Transcultural lessons in the Management of Heart Failure TRANSMEDHF$120,000
R21 · FY2018 · HL
MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSOCLEROSIS (MAGMA)$628,461
R01 · FY2017 · HL · contact PI
EXercise MRI evaluation of HIV-PAH Longitudinal Determinants (EXHALTED)$597,635
R01 · FY2017 · HL · contact PI
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$562,302
U01 · FY2017 · ES
Air Pollution and Hypertension: Vascular Mechanisms$501,872
R01 · FY2017 · ES · contact PI
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure$433,436
R01 · FY2017 · ES · contact PI
Epigenomics of Air Pollution Driven Inflammation, Obesity, and Insulin Resistance$100,994
U01 · FY2017 · ES
Air Pollution and Hypertension: Vascular Mechanisms$72,572
R01 · FY2017 · ES · contact PI
Interdisciplinary Training Program in Cardiovascular Disease$3,668
T32 · FY2017 · HL
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosoclerosis (MIRACULOUS)$689,663
R01 · FY2016 · HL · contact PI
EXercise MRI evaluation of HIV-PAH Longitudinal Determinants(EXHALTED)$563,391
R01 · FY2016 · HL · contact PI
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$556,576
U01 · FY2016 · ES
Epigenomics of Air Pollution driven Inflammation, Obesity and Insulin Resistance$530,574
U01 · FY2016 · ES
Interdisciplinary Training Program in Cardiovascular Disease$496,003
T32 · FY2016 · HL
Air Pollution and Hypertension: Vascular Mechanisms$358,833
R01 · FY2016 · ES · contact PI
Air pollution and hypertension: vascular mechanisms$78,688
R01 · FY2016 · ES · contact PI
EXercise MRI evaluation of HIV-PAH Longitudinal Determinants(EXHALTED)$549,927
R01 · FY2015 · HL · contact PI
Air pollution and hypertension: vascular mechanisms$443,570
R01 · FY2015 · ES · contact PI
Air pollution and hypertension: vascular mechanisms$450,000
R01 · FY2014 · ES · contact PI
Diet-Environment Interactions in Inflammation$358,086
R01 · FY2014 · ES · contact PI
Environmental Triggers of Cardiometabolic Disease$294,020
R01 · FY2014 · ES · contact PI
Environmental Triggers of Cardiometabolic Disease$37,192
R01 · FY2014 · ES · contact PI
Environmental Triggers of Cardiometabolic Disease$377,355
R01 · FY2013 · ES · contact PI
Diet-Environment Interactions in Inflammation$376,648
R01 · FY2013 · ES · contact PI
Environmental Triggers of Cardiometabolic Disease$424,280
R01 · FY2012 · ES · contact PI
Diet-Environment Interactions in Inflammation$373,462
R01 · FY2012 · ES · contact PI
Multivalent Theranostics for Inflammation$242,112
R21 · FY2012 · HL · contact PI
Environmental Triggers of Cardiometabolic Disease$443,919
R01 · FY2011 · ES · contact PI
Diet-Environment Interactions in Inflammation$351,810
R01 · FY2011 · ES · contact PI
T Regulatory Cells as Determinants of Inflammation in Adipose Tissue$226,463
R21 · FY2011 · DK · contact PI
Multivalent Theranostics for Inflammation$215,280
R21 · FY2011 · HL · contact PI
Air Pollution and Hypertension: Vascular Mechanisms$528,320
R01 · FY2010 · ES · contact PI
Diet-Environment Interactions in Inflammation$352,646
R01 · FY2010 · ES · contact PI
T Regulatory Cells as Determinants of Inflammation in Adipose Tissue$190,625
R21 · FY2010 · DK · contact PI
Air Pollution and Hypertension: Vascular Mechanisms$594,544
R01 · FY2009 · ES · contact PI
Air Pollution and Hypertension: Vascular Mechanisms$465,834
R01 · FY2008 · ES · contact PI
Air Pollution and Hypertension: Vascular Mechanisms$523,497
R01 · FY2007 · ES · contact PI
Air Pollution Exposure/Atherosclerosis:Vascular Mechanism$276,356
R01 · FY2007 · ES · contact PI
Air Pollution Exposure/Atherosclerosis:Vascular Mechanism$35,000
R01 · FY2007 · ES · contact PI
Air Pollution Exposure/Atherosclerosis:Vascular Mechanis$352,208
R01 · FY2006 · ES · contact PI
Air Pollution Exposure/Atherosclerosis:Vascular Mechanis$339,149
R01 · FY2005 · ES
Air Pollution Exposure/Atherosclerosis:Vascular Mechanis$320,488
R01 · FY2004 · ES
Replication deficient adenovirus containing VEGF cDNA to ischemic lower limb of$0
M01 · FY2002 · RR
Evaluation of losartan in preventing age dependent endothelial dysfunction$0
M01 · FY2002 · RR
Depression and endothelial function--The DEPEND study$0
M01 · FY2002 · RR
Analysis of vascular function with adriamycin administration$0
M01 · FY2002 · RR
Analysis of vascular function with adriamycin administration$0
M01 · FY2000 · RR
Evaluation of losartan in preventing age dependent endothelial dysfunction$0
M01 · FY2000 · RR
Depression and endothelial function--The DEPEND study$0
M01 · FY2000 · RR
Replication deficient adenovirus containing VEGF cDNA to ischemic lower limb of$0
M01 · FY2000 · RR